READ-ONLY DIGITIZATION RESULT
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.
J Clin Oncol · 2026-Jan-20 · PMID 41370738
Panel C质量警告待 EXE 对齐验证
TTNT
FIG 2. (A) PFS as assessed by IRC, (B) EFS, and (C) TTNT in the intention-to-treat population. a HR and corresponding 95% CI were determined by using stratified Cox proportional hazard model. b P value was determined by using stratified log-rank test. EFS, event-free survival; HR, hazard ratio; IRC, independent review committee; PFS, progression-free survival; PomDex, pomalidomide and dexamethasone; TTNT, time to next treatment; VenDex, venetoclax and dexamethasone.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T17:02:22+00:00 |